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would be necessary in 26 of the 141 
patients studied. All but one of these 
patients belonged to the cohort that devel-
oped radiation pneumonitis. The mean 
clinically prescribed dose to this pneumo-
nitis population was 64.7 Gy as opposed to 
51.8 Gy predicted to be safe by the model. 
For a subset of the remaining patients, 
the dose could be slightly increased or 
decreased. This finding is intriguing keep-
ing in mind that dose escalation in lung 
radiotherapy is thought to substantially 
increase local tumor control and ulti-
mately survival.4 Instead of decreasing 
the dose to prevent patients from develop-
ing unwanted side effects, more tailored 
solutions are feasible. van Baardwijk et 
al.5 successfully pioneered an individual-
ized approach escalating dose to maxi-
mal tolerance while keeping within the 
normal-tissue constraints, both theoreti-
cally and clinically. Both acute and late 
toxicity were acceptable. Additionally, 
MAASTRO clinic is currently conduct-
ing a randomized phase II trial including 
18F-fluorodeoxyglucose-positron emis-
sion tomography information for tumor 
(subvolume) boosting (NCT01024829). 
On the basis of a recent in silico study,3 
Radboud University Nijmegen Medical 
Centre is carrying out the Individualized 
Dose Escalation in Advanced stage non-
small cell Lung cancer using Volumetric 
Modulated Arc Therapy (IDEAL-VMAT) 
study (NCT01577212), whereby the 
irradiation dose is increased on an indi-
vidual basis, taking into account multiple 
 normal-tissue constraints.
For patients with both an unfavor-
able genetic profile and dose distribu-
tion, the radiation dose that can be safely 
administered on the basis of the proposed 
model is probably not curative. Therefore, 
the treating radiation oncologist may opt 
for a palliative protocol thereby deceler-
ating tumor progression and alleviating 
tumor-associated complaints while pre-
venting patients from unnecessary treat-
ment-related side effects.
In summary, this article on model-
based prescription provides new, yet 
prospectively unvalidated, tools for indi-
vidualized dose-prescription in non–
small-cell lung cancer patients. Radiation 
oncologists are encouraged to enhance 
radiation dose in patients with a favorable 
profile while seeking alternative thera-
peutic options in the remaining patients.
To the Editor:
With great interest, we read the 
recent publication by Vinogradskiy et 
al.1 The authors apply their radiation 
pneumonitis prediction model combin-
ing dose-volume and genetic compo-
nents (single-nucleotide polymorphisms 
[SNPs]) for isotoxic mean lung dose 
determination. The five SNPs were 
found to predict for radiation pneumoni-
tis and interestingly, they do not directly 
relate to lung injury, but rather to cellular 
repair and the tumor microenvironment.
The authors state that radiation 
pneumonitis is the dominant dose- 
limiting constraint in thoracic radiother-
apy. This may have been the case for the 
cohort studied for 19% of the patients, 
mostly treated with three-dimensional 
conformal radiotherapy developed radi-
ation pneumonitis of grade 3 or higher. 
With the introduction of highly confor-
mal radiotherapy delivery techniques 
and by abandoning elective nodal irra-
diation, acute grade 3 esophagitis is 
increasingly the dose-limiting toxicity 
based both on clinical experience2 and 
in silico studies.3 As opposed to radia-
tion pneumonitis, this burdensome side 
effect is not fatal but gradually develops 
during the course of (chemo)radiother-
apy, lasting for several weeks thereaf-
ter necessitating analgesic medication 
and dietary alterations in the majority 
of patients. Moreover, late esophageal 
sequelae may develop, adversely influ-
encing the patients’ quality of life.
Vinogradskiy et al.1 found that on 
the basis of the isotoxic physico-genetic 
model a reduction in prescribed dose 
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and duration are under-reported by 
patients and therefore impossible to 
completely exclude from any esti-
mate of the association between the 
two diseases which are both strongly 
related to smoking.
Although we accept that our 
study does not completely exclude an 
independent effect of COPD on the 
risk of lung cancer, our own opinion 
is that the remaining association can 
be explained by residual confounding 
and that any truly independent effect 
would be very small, and certainly 
lower than a twofold increase. The 
importance of our interpretation lies 
in the allocation of resources in lung 
cancer research, which we believe 
should not be focused on the pursuit of 
a potential molecular link, but rather 
on early detection, novel and improved 
treatments, and smoking cessation.
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of the tyrosine kinase domain of epider-
mal growth factor receptor (EGFR), 
gefitinib and erlotinib, in patients 
with EGFR mutations result in 70% 
to 80% responses.1,2 Ninety percent of 
these consist of deletions of exon 19 
and p.L858R mutations on exon 21.2 
However, through diverse mechanisms3 
resistance will eventually appear. There 
are also a minority of infrequent EGFR 
mutations at diagnosis whose predictive 
role is poorly characterized.4
We present two cases of patients 
diagnosed with a lung adenocarci-
noma harboring rare EGFR mutations 
that received treatment with gefitinib. 
Mutational analysis was performed by 
polymerase chain reaction amplification 
of exons 18, 19, 20 and 21 of the EGFR 
gene and exon 1 of the KRAS gene fol-
lowed by direct sequencing using BigDye 
3.1 (Applied Biosystems, Foster City, 
CA) and analysis in a Genetic Analyzer 
3500Dx (Applied Biosystems).
CASE 1
A white, 81-year-old, male 
exsmoker was diagnosed in July 2010 of 
a stage IIIA (T4N0M0) lung adenocarci-
noma. Molecular analysis demonstrated 
the presence of a p.R836C mutation in 
exon 21 of the EGFR gene. He began 
first-line chemotherapy with a platinum 
doublet. Response assessment by com-
puted tomography scan showed stabiliza-
tion. However, because of symptomatic 
Two Rare Exon 21 
EGFR Mutations in 
Patients Treated with 
Gefitinib
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To the Editor:
Treatment of non–small-cell lung 
cancer patients with reversible inhibitors 
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progression he started treatment with 
gefitinib 250 mg/day. In January 2011 
he was admitted in hospital because of 
increasing dyspnoea and pain. The com-
puted tomography scan showed progres-
sion of the tumor with appearance of 
pleural effusion. The study of the fluid 
confirmed the diagnosis of metastasis 
from adenocarcinoma harboring the 
p.R836C mutation on exon 21 (Fig. 1A). 
No p.T790M mutation on exon 20 or 
hepatocyte growth factor receptor (MET) 
amplification was detected. Progressive 
disease led to rapid deterioration of per-
formance status and the patient died in 
early March 2011.
CASE 2
A white, 54-year-old, heavy 
smoker man was diagnosed in May 
2011 with a lung adenocarcinoma stage 
IIIB (T4N2M0) not suitable for radical 
treatment. Evaluation of EGFR muta-
tional status demonstrated the presence 
of the p.T854S mutation in exon 21. 
No wild-type allele was detected in this 
position, indicating that the mutation 
was either hemizygous or homozygous 
(Fig. 1B). He started treatment with 
gefitinib and early (6 weeks) assessment 
by computerized tomography demon-
strated progressive disease. He received 
subsequent lines of treatment with sta-
ble disease as best response. Local and 
central nervous system progression led 
FIGURE 1.  Sequencing chromatograms showing EGFR mutations affecting cases 1 
and 2. A, Case 1-arginine(R) to cysteine (C) substitution at amino acid position 836 
(p.R836C) resulting from a CGC→TGC exchange. B, Case 2-threonine (T) to serine 
(S) substitution at amino acid position 854 (p.T854S) resulting from a ACA→TCA 
exchange.
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